Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whether patients with resected stage IIA colon cancer may benefit from adjuvant chemotherapy (Abstract TPS261).
Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97...
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceed...
Brian M. Wolpin, MD, of Dana-Farber Cancer Institute, discusses a noninvasive blood test evaluating methylation of circulating free DNA. In his study, the blood test detected...
Eyal Meiri, MD, of the Cancer Treatment Centers of America at Southeastern Regional Medical Center, discusses his findings on heavily pretreated patients with colorectal canc...
Thibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy ...
